We are live on ! Find out more
ADIL

Adial Pharmaceuticals
ADIL

19 hedge funds and large institutions have $5.33M invested in Adial Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

75% more capital invested

Capital invested by funds: $3.04M → $5.33M (+$2.29M)

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

6% more funds holding

Funds holding: 18 → 19 (+1)

0% less ownership

Funds ownership: 0.01% → 0.01% (-0%)

Holders
19
Holders Change
+1
Holders Change %
+5.56%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
7
Reduced
2
Closed
4
Calls
$224K
Puts
–
Net Calls
+$224K
Net Calls Change
+$224K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$132K
2
Millennium Management
Millennium Management
New York
+$56.5K
3
Charles Schwab
Charles Schwab
California
+$39.8K
4
OC
Oppenheimer & Co
New York
+$35.6K
5
NP
NorthRock Partners
Minnesota
+$33.5K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$79K
2
GG
Golden Green
South Carolina
-$63K
3
Citadel Advisors
Citadel Advisors
Florida
-$52K
4
PAG
Private Advisor Group
New Jersey
-$4.19K
5
BlackRock
BlackRock
New York
-$2.09K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.55M +$31.4K +15 +2%
BlackRock
2
BlackRock
New York
$837K -$2.09K -1 -0.3%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$412K +$27.2K +13 +9%
State Street
4
State Street
Massachusetts
$215K +$4.19K +2 +3%
Morgan Stanley
5
Morgan Stanley
New York
$173K +$132K +63 +6,300%
OC
6
Oppenheimer & Co
New York
$165K +$35.6K +17 +38%
Commonwealth Equity Services
7
Commonwealth Equity Services
Massachusetts
$156K +$25.1K +12 +26%
PAG
8
Private Advisor Group
New Jersey
$152K -$4.19K -2 -3%
Dimensional Fund Advisors
9
Dimensional Fund Advisors
Texas
$135K – – –
Northern Trust
10
Northern Trust
Illinois
$126K +$25.1K +12 +34%
Brown Advisory
11
Brown Advisory
Maryland
$112K – – –
Millennium Management
12
Millennium Management
New York
$73K +$56.5K +27 New
RW
13
Rede Wealth
Virginia
$65K – – –
Charles Schwab
14
Charles Schwab
California
$50K +$39.8K +19 New
NP
15
NorthRock Partners
Minnesota
$43K +$33.5K +16 New
Osaic Holdings
16
Osaic Holdings
Arizona
$35K – – –
UBS Group
17
UBS Group
Switzerland
$19K +$14.7K +7 New
BFEC
18
Benjamin F. Edwards & Company
Missouri
$4K +$4.19K +2 New
Wells Fargo
19
Wells Fargo
California
$3K – – –
VF
20
Virtu Financial
New York
– -$79K -50 Closed
GG
21
Golden Green
South Carolina
– -$63K -40 Closed
Citadel Advisors
22
Citadel Advisors
Florida
– -$52K -32 Closed
TRCT
23
Tower Research Capital (TRC)
New York
– -$2.09K -1 Closed

ADIL Hedge Fund Activity: Q3 2021 in Review

19 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q3 2021, worth a combined $5.33M — up 75% from $3.04M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ADIL positions and 4 closed out — a net gain of 1 holder — while 7 added to existing stakes and 2 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $132K. The largest seller was Virtu Financial, exiting entirely with an estimated $79K sold.

  • 19 institutional investors held Adial Pharmaceuticals (ADIL) as of Q3 2021, up from 18 in Q2 2021.
  • Funds reported $5.33M of Adial Pharmaceuticals stock for Q3 2021, up 75% quarter-over-quarter.
  • 5 funds opened new Adial Pharmaceuticals positions in Q3 2021 and 4 closed out, a net change of +1 holder.
  • The largest Adial Pharmaceuticals buyer in Q3 2021 was Morgan Stanley, an estimated $132K added.
  • The largest Adial Pharmaceuticals seller in Q3 2021 was Virtu Financial, an estimated $79K sold.

Based on aggregated 13F filings for Q3 2021.